DeciBio

We are pleased to announce the speakers for our upcoming webinar, Emerging Applications and Platforms in Liquid Biopsy, on Wednesday, November 6, 2024. Join us for this discussion led by: Rehan Verjee, Chief Executive Officer, Precede Biosciences Dawn Mattoon, Chief Executive Officer, Mercy BioAnalytics, Inc. Peter B., Chief Medical Officer, DELFI Diagnostics Sarah Clancey Overton, Director of RCM, Velsera Mark Sausen, Executive Director, Head of Technology Innovation, PGDx, Labcorp Together, our distinguished speakers will explore advancements in liquid biopsy, including innovations in early cancer detection, epigenomics, and targeted therapies, while addressing challenges in access and reimbursement. Webinar Details ?? Date: Wednesday, November 6, 2024 ? Time: 9:00 AM - 10:00 AM PST ??Register here: https://lnkd.in/gKZBQanP #precisionmedicine #liquidbiopsy

Check out our team's work in the latest issue of Pharma Focus Europe Carl Schoellhammer, Aditi Ghalsasi, and Cassidy Humphreys share their perspectives and analysis on the evolution of #mRNA therapeutics from recent advances, barriers and challenges, to charting a path forward. Link to digital magazine here: https://lnkd.in/gQUdzfZb #advancedtherapies #precisionmedicine

Megan Nacar and Tina Wang are back from the Personalized Medicine Conference (PMC) in Boston, which reinvigorated our firm’s commitment to accelerating innovation in precision medicine. We are proud to be a PMC member and to be a part of the diverse ecosystem of stakeholders and organizations the PMC brings together. See their key takeaways from the annual meeting below, with developments across the Dx investment landscape, AI, and multi-cancer early detection. #PMC2024 #PrecisionMedicine

AI-Powered Drug Discovery and Antibody Innovation: DeciBio Q&A with Absci Leadership In our latest Q&A, Luka Jelcic spoke with Sean McClain, Founder & CEO, and Zach Jonasson, CFO & CBO of Absci, about the role of AI in revolutionizing drug discovery. They shared valuable insights into how generative AI is being applied to design antibodies and address previously challenging drug targets, reshaping the biotech landscape.? Here's a quick summary of the conversation: ? AI is transforming the design of antibodies and therapeutics, making previously difficult targets more accessible for treatment development. ? The journey of an AI-first company shifting into a company with its own pipeline and the key challenges involved ? The value of AI-first and biopharma partnerships and how the landscape will change over time Check out the full interview here: https://lnkd.in/gMt9fjsB Sign up for our AI newsletter to stay updated on the latest breakthroughs in AI-driven drug discovery and more: https://lnkd.in/gKQn7_zp #AI #DrugDiscovery #AntibodyInnovation

Exciting News: Our Single Cell Analysis Market Report: Sixth Edition is Coming Soon! We're thrilled to announce the upcoming release of our latest Single Cell Analysis Market Report. The sixth edition of this report takes a completely updated and comprehensive look at the SCA market, featuring new coverage of emerging technologies such as instrument-free, multi-omic, and functional single cell assays.? What's Inside? ? In-depth analysis of market drivers, moderators, and trends ? Market sizing and growth rates ? Competitive analysis of new and emerging single cell technologies Early-Bird Special: Pre-purchase now and lock in a 10% early-bird discount! Head over to our website to take advantage of this offer: https://lnkd.in/gdPKWWci Sign up to be notified when the report is published and gain early access: https://lnkd.in/gWAAH-SS #SingleCell #MarketReport #PrecisionMedicine

Wrapping up a whirlwind month of conferences with a strong finish! Tina Wang will be attending the 6th Annual International Society of Liquid Biopsy's Congress for Liquid Biopsy, November 23-24 at the Gaylord Rockies Convention Center in Denver, CO. After an exciting month packed with impactful events, we're thrilled to round it out by joining the conversation on cutting-edge advancements in the liquid biopsy space. Connect with Tina & learn more about our work and available content in Liquid Biopsy: ? Emerging Applications & Platforms in Liquid Biopsy (On-Demand Webinar): https://lnkd.in/gM8kp6pr ? Oncology Liquid Biopsy Market Report 2024-2029: https://lnkd.in/gh7XPQ3p ? Our Partnership with the Precision Cancer Consortium #ISLB2024 #LiquidBiopsy

Liquid biopsies (LBx) are revolutionizing cancer diagnostics, yet adoption varies widely across clinical and institutional settings. Insights from Rishikesh Kayathi latest analysis, powered by our NGS DxBook, highlight key trends and challenges shaping the field: 1. Therapy Selection Dominates, but Adoption Remains Limited While therapy selection remains the most mature clinical application for LBx, its integration into laboratory workflows is still evolving. Currently, only ~33% of surveyed labs incorporate LBx, signaling significant growth potential as key adoption barriers are addressed. 2. Institutional Adoption Shows Significant Variability Academic Medical Centers (AMCs) and national reference labs are leading the way in LBx adoption, with BioPharma also gaining momentum. However, community hospitals are slower to adopt, presenting an opportunity to expand education and outreach to ensure broader access. 3. Barriers to Adoption Persist, Widespread adoption of LBx is hindered by: - Inconsistent reimbursement policies - Limited definitive clinical utility data - A lack of end-to-end (E2E) workflows Despite these challenges, the potential for LBx to transform precision oncology remains clear: - Comprehensive Genomic Profiling (CGP): Doubling detection rates of actionable genomic alterations compared to smaller panels, enabling better biomarker-matched therapy decisions. - Emerging Applications: Innovations like real-time gene functionality assessment are advancing precision treatments, including next-generation therapies like antibody-drug conjugates (ADCs). 4. International Adoption Lags but Shows Promise While Europe trails the U.S. in LBx adoption, progressive labs across the region are closing the gap, as reflected in our dataset. Liquid biopsies hold immense promise for the future of oncology, and the journey toward broader adoption continues to be shaped by innovation and collaboration. Want to learn more? Connect with Rishikesh at #AMP2024 next week and share your observations or questions!

Who's headed to the 15th Annual Jefferies London Healthcare Conference? We are looking forward to joining leading global, public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors at Jefferies London Healthcare Conference 2024 taking place November 19–21. Meet with our partner team Stephane Budel and Katie Maloney and to discuss all things #precisionmedicine #digitalpathology #NGS This year’s gathering marks the 15th anniversary of the largest healthcare-dedicated conference in Europe and will bring together leading executives to address near-and long-term investment opportunities as well as the current trends driving healthcare in the U.S. and internationally. Stay tuned for updates about the event with?#JefferiesHealthcare

Meet Tina Wang! Tina is a senior project leader in our San Francisco office. With almost 6 years at the firm, she has led projects across diagnostics, research tools, and health IT industries. She has a strong focus on precision oncology diagnostics, including genomic profiling, liquid biopsy, digital pathology, and radiomics. Prior to joining DeciBio, Tina studied Global Health at USC. Beyond client engagements, Tina is deeply involved in many internal initiatives and co-leads our Women* in Consulting group. Tina brings a population health and impact-driven perspective to her work, shaping her approach to advancing innovation in precision medicine. Meet with Tina at the upcoming ISLB 2024 - 6th Annual Congress of Liquid Biopsy, from November 23-25 in Denver, Colorado. Check out her latest Radiomics Q&A here: https://lnkd.in/gTKMP8hU Want to be a part of our team? Check out our open positions or learn more about us on our website: https://lnkd.in/gteq7n_F #meettheteam #precisionmedicine #ISLB2024

Our team has packed our passports and is excited to head to Vancouver next week for the 30th Annual Association for Molecular Pathology (AMP) Meeting! We’re thrilled to be joining our peers in advancing molecular diagnostics and connecting with industry leaders. Meet with our team members David Cavanaugh, Miguel Edwards, Ph.D., Michelle Atallah, Rishikesh Kayathi, and Megan Nacar. With experts across precision medicine, partnerships, and innovation, we’re ready to share how we support our clients in navigating the rapidly evolving molecular pathology landscape. We're also proud to feature DeciBio DxBooks – our market intelligence product led by Michelle and Rishi – which provide critical insights into both infectious diseases and next generation sequencing oncology. These resources are designed to empower organizations with up-to-date intelligence on NGS advancements, market trends, and adoption across therapeutic areas. Whether you're exploring the latest developments in infectious disease diagnostics or oncology applications, DxBooks is your essential companion for staying informed and making strategic decisions. Heading to AMP? Drop a line in the comments to connect with our team and discover how DeciBio can support your molecular pathology initiatives. We look forward to seeing you there! #AMP2024 #PrecisionMedicine